Meets Primary Endpoint

Related by string. Meet Primary Endpoint * meeting . meets . meet . MEETING : Town Meeting . General Meeting . Will Meet Tall . Annual Shareholder Meeting / pri mary . PRIMARY . primary : Primary Care Trust . Primary Leaving Examinations . Primary Care Trusts / Endpoints . EndPoint . endpoints : primary efficacy endpoint . Secondary endpoints include . secondary efficacy endpoints * *

Related by context. Frequent words. (Click for all words.) 86 Drug Candidate 86 Completes Enrollment 86 Phase III Trial 85 Patient Enrollment 85 Clinical Trial Results 85 Pivotal Phase III 85 Pivotal Phase 85 Phase III Clinical Trial 84 Initiate Phase 83 Presents Positive 82 Initiates Phase 82 Preclinical Data 81 FDA Accepts 81 Single Dose 81 Chronic Hepatitis C 81 Generic Version 81 Well Tolerated 80 Pivotal Trial 80 Metastatic Colorectal Cancer 80 Monotherapy 80 Patients Treated 80 FDA Clears 79 II Clinical Trial 79 Pulmonary Arterial Hypertension 79 Elderly Patients 79 Metastatic Melanoma 78 Positive Opinion 78 Aliskiren 77 Overactive Bladder 77 Study Demonstrates 77 Low Dose 77 Significantly Reduces 76 Combination Therapy 76 Advanced Prostate Cancer 76 Benign Prostatic Hyperplasia 76 Patent Covering 76 Heart Failure Patients 76 Recombinant Human 76 Develop Novel 76 Postmenopausal Women 76 Announces Initiation 75 Prostate Cancer Patients 75 RNAi Therapeutics 75 Monoclonal Antibody 75 Cholesterol Drug 75 Tolerability 75 Epratuzumab 75 Tumor Growth 75 Patients Undergoing 75 Bevacizumab 74 Extended Release 74 FDA Clearance 74 Receives FDA Clearance 74 Kuvan R 74 MKC# 74 Diabetic Patients 74 Allergic Rhinitis 74 Lung Cancer Patients 74 Bortezomib 74 Reduces Risk 74 Irinotecan 74 Dasatinib 74 FDA Approves 74 Shows Promise 74 refractory chronic lymphocytic 74 Blood Thinner 73 J Am Coll 73 Capecitabine 73 Cethromycin 73 Microplasmin 73 Diabetic Macular Edema 73 Inhibits 73 Chronic Heart Failure 73 Gastric Cancer 73 J Am Acad 73 Small Molecule 73 Panzem R 72 Ischemic 72 Ofatumumab 72 Enoxaparin 72 Increases Risk 72 Etanercept 72 Gemzar ® 72 Daclizumab 72 Drug Resistant 72 KRN# 72 Venous Thromboembolism 72 Voreloxin 72 Boceprevir 72 Lenalidomide 72 Pirfenidone 72 liposomal formulation 72 Chronic Lymphocytic Leukemia 72 Announces Presentation 72 Antipsychotic 72 Announces Publication 71 Adalimumab 71 Belimumab 71 Tesetaxel 71 metastatic castration resistant 71 Meta Analysis

Back to home page